Century Therapeutics Inc. has announced its first program for type 1 diabetes, CNTY-813. The program comprises induced pluripotent stem cell (iPSC)-derived β islets engineered with the company’s proprietary Allo-Evasion 5.0 technology, designed to protect from T-cell, NK-cell and humoral immune rejection, with the goal of durable glycemic control without the need for systemic immunosuppression.
Hutchmed (China) Ltd. has developed HMPL-A251, a novel HER2 antibody-drug conjugate (ADC) designed to deliver a potent PI3K/PIKK inhibitor directly to tumor cells.
Melanocortin-4-receptor MC4R is a crucial molecule involved in energy homeostasis, feeding behavior and metabolism, and loss-of-function mutations in this gene are the main monogenic cause of early-onset obesity. Congruence Therapeutics Inc. has developed a small molecule, CGX-926, that corrected MC4R deficiency and restored its cell-surface expression and function.
Suzhou Junjian Yifang Biopharmaceutical Co. Ltd. has described pyrimido[6,1-a]isoquinolin-4-one derivatives acting as dual phosphodiesterase PDE3 and PDE4 inhibitors reported to be useful for the treatment of asthma and chronic obstructive pulmonary disease.
Hangzhou Synrx Therapeutics Technology Co. Ltd. has divulged crystalline salts of DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.
3H Pharmaceuticals Co. Ltd. has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Innovstone Therapeutics Ltd. has disclosed integrin αLβ2 (LFA-1)/ICAM-1 interaction inhibitors and/or RASP-trapping agents reported to be useful for the treatment of dry eye syndrome.
CIS Biopharma AG recently presented an antibody-drug conjugate (ADC) targeting the L1 cell adhesion molecule (L1CAM/CD171) as a potential candidate for the treatment of advanced tumors.
Two attractive drug targets in tumors are carbonic anhydrase IX (CAIX), which helps maintain pH homeostasis in the hypoxic tumor, and glutathione peroxidase 4 (GPX4), which can reduce oxidative stress. Researchers from Università degli Studi di Firenze and collaborators aimed to inhibit both CAIX and GPX4 simultaneously.
RSS
